Shareholders meeting

Ref. no.:WOCK/SEC/SE/2026-27/024 17th July, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers, Dalal Street Bandra Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Dear Sir/Madam, Sub: Notice of 27th Annual General Meeting and the Annual Report of the Company for the Financial Year 2025-26 The 27th Annual General Meeting (‘27th AGM’) of the Members of Wockhardt Limited will be held on Monday, 10th August, 2026 at 3:30 p.m. (IST), through Video Conferencing (‘VC’)/ Other Audio Visual Means (‘OAVM’). Pursuant to Regulations 29, 30 and 34(1) of the SEBI Listing Regulations, we submit herewith the Notice convening the 27th AGM and the Annual Report for the Financial Year 2025-26, including the Business Responsibility and Sustainability Report of the Company for the period (‘Annual Report’). Pursuant to Regulation 36 of the SEBI Listing Regulations, the Notice of the 27th AGM and Annual Report are sent through the electronic mode to the Members of the Company whose e-mail addresses are registered with the Depositories/RTA and letters providing web inks and QR codes for accessing the Notice of the 27th AGM and Annual Report are sent to the Members whose e- mail addresses are not registered. Kindly take the same on record. Thanking you, For Wockhardt Limited Rashmi Mamtura Company Secretary Encl: a/a WOCKHARDT LIMITED Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar – 431 006 Global Headquarters: Wockhardt Towers, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 CIN: L24230MH1999PLC120720 Telephone: 91-240-6694444 Email ID: investorrelations@wockhardt.com; Website: www.wockhardt.com NOTICE Notice is hereby given that the Twenty-Seventh Annual General Meeting (“AGM”) of the Members of WOCKHARDT LIMITED will be held on Monday, August 10, 2026 at 3:30 p.m. (IST) through Video Conferencing (“VC”)/Other Audio Visual Means (“OAVM”) to transact the following businesses: ORDINARY BUSINESS: 1. Adoption of Audited Financial Statements: To receive, consider and adopt: a. the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon; and b. the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Report of the Auditors thereon. 2. Appointment of Director retiring by rotation: To appoint a Director in place of Ms. Zahabiya Khorakiwala (DIN: 00102689), who retires from office by rotation and, being eligible, offers herself for re-appointment. SPECIAL BUSINESS: 3. Ratification of remuneration payable to the Cost Auditors for the Financial Year 2026-27: To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 and the Companies (Cost Records and Audit) Rules, 2014, as amended (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of ₹ 3,85,000 (Rupees Three Lakh Eighty-Five Thousand Only) plus applicable taxes and reimbursement of out-of-pocket expenses payable to Kirit Mehta & Co. LLP, Cost Accountants (Firm Registration No. 000353), appointed by the Board of Directors of the Company as Cost Auditors for conducting the Cost Audit of the Company for the financial year ending on March 31, 2027, be and is hereby ratified and confirmed; and RESOLVED FURTHER THAT the Board of Directors of the Company (which term shall be deemed to include any Committee thereof, which may exercise its powers, including the powers, conferred by this resolution) be and is hereby authorized to do all such acts and take all such steps as may be necessary, proper or expedient to give effect to the said resolution.” 4. Revision of the remuneration payable to Dr. Habil Khorakiwala (DIN: 00045608), Executive Chairman: To consider and, if thought fit, to pass the following resolution as a Special Resolution: “RESOLVED THAT in accordance with the provisions of Sections 196, 197, 198 and other applicable provisions of the Companies Act, 2013 read with Schedule V thereto and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 17(6)(e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall be deemed to include any Committee thereof, which may exercise its powers, including the powers, conferred by this resolution), and subject to other requisite approvals as may be necessary, consent of the Members be and is hereby accorded for payment of remuneration (including minimum remuneration in the event of WOCKHARDT LIMITED absence or inadequacy of profits) to Dr. Habil Khorakiwala (DIN: 00045608), Executive Chairman, in such manner and on such terms and conditions as may be determined by the Board from time to time, for the period of three years commencing from March 1, 2027 till February 28, 2030, provided that the amount of such remuneration including basic salary and perquisites and allowances as per Company’s policies shall not exceed in aggregate the amount of ₹ 10 Crore per annum for the period commencing from March 1, 2027 till February 29, 2028, and thereafter may be revised by the Board, based on the recommendation of the Nomination and Remuneration Committee, from time to time, subject to an overall ceiling of ₹15 Crore per annum; RESOLVED FURTHER THAT the Contribution to Provident Fund, Superannuation Fund and Gratuity as per Company’s rules, and encashment of leave at the end of the tenure shall not be included while computing the aforesaid ceiling on remuneration; RESOLVED FURTHER THAT the Board be and is hereby authorized to settle any questions, difficulties or doubts that may arise in this regard and to do all such acts, deeds and things including any modification in the structure or composition of remuneration as may be approved by the Board from time to time, provided the aggregate remuneration does not exceed the aforesaid limits and to execute all such documents, instruments and writings as may be required and to delegate all or any of its powers to any Committee of Directors or any Director or Officer of the Company for the purpose of giving effect to this resolution; and RESOLVED FURTHER THAT save as expressly modified herein, all the other terms and conditions of the Special Resolution approved and passed by the Members in their Twenty-fifth Annual General Meeting held on June 28, 2024, for appointment and remuneration of Dr. Habil Khorakiwala, as the Executive Chairman of the Company, shall continue to remain in full force and effect.” 5. Approval of Material Related Party Transactions with Wockhardt Bio AG: To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, (the “SEBI Listing Regulations”), Section 188 and other applicable provisions of the Companies Act, 2013 (the “Act”) read with Rules made thereunder, other applicable laws/statutory provisions, if any, (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the Company’s Policy on Related Party Transac [Showing first 8,000 characters — download PDF for full document]